| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
| |
||
(Address of principal executive offices) |
(Zip Code) |
| Title of each class registered |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
the units |
||||
the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 |
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
Page No. |
||||||
| PART I. FINANCIAL INFORMATION |
||||||
| Item 1. |
1 |
|||||
1 |
||||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
| Item 2. |
20 |
|||||
| Item 3. |
22 |
|||||
| Item 4. |
22 |
|||||
| PART II. OTHER INFORMATION |
||||||
| Item 1. |
24 |
|||||
| Item 1A. |
24 |
|||||
| Item 2. |
24 |
|||||
| Item 3. |
24 |
|||||
| Item 4. |
24 |
|||||
| Item 5. |
24 |
|||||
| Item 6. |
25 |
|||||
26 |
||||||
• |
our ability to select an appropriate target business or businesses; |
• |
our ability to complete our initial business combination; |
• |
our expectations around the performance of the prospective target business or businesses; |
• |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
• |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
• |
our potential ability to obtain additional financing to complete our initial business combination; |
• |
our pool of prospective target businesses; |
• |
our ability to consummate an initial business combination due to the uncertainty resulting from the COVID-19 pandemic and other events (such as an outbreak or escalation of armed hostilities or acts of war, terrorist attacks, natural disasters or other significant outbreaks of infectious diseases); |
• |
the ability of our officers and directors to generate a number of potential business combination opportunities; |
• |
our public securities’ potential liquidity and trading; |
• |
the lack of a market for our securities; |
• |
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
• |
the trust account not being subject to claims of third parties; or |
• |
our financial performance following our initial public offering. |
March 31, 2022 |
December 31, 2021 |
|||||||
(Unaudited) |
||||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash |
$ | $ | ||||||
| Prepaid expenses |
||||||||
| |
|
|
|
|||||
| Total current assets |
||||||||
| Investments held in Trust Account |
||||||||
| |
|
|
|
|||||
| TOTAL ASSETS |
$ |
$ |
||||||
| |
|
|
|
|||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | $ | ||||||
| Accrued offering costs |
||||||||
| Due to Sponsor |
||||||||
| Accrued expenses |
||||||||
| Accrued expenses - related party |
||||||||
| |
|
|
|
|||||
| Total current liabilities |
||||||||
| Deferred underwriting fee payable |
||||||||
| |
|
|
|
|||||
| Total liabilities |
||||||||
| Commitments and Contingencies (Note 6) |
||||||||
| Class A ordinary shares subject to possible redemption, and shares at redemption value of $ at March 31, 2022 and December 31, 2021, respectivel y |
|
|||||||
| Shareholders’ Deficit |
||||||||
| Preference shares, $ |
||||||||
| Class A ordinary shares, $ e xcluding |
||||||||
| Class B ordinary shares, $ at March 31, 2022 and December 31, 2021, respectively (1) |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total Shareholders’ Deficit |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
$ |
$ |
||||||
| |
|
|
|
|||||
(1) |
Includes up to |
Three Months Ended March 31, 2022 |
For the Period From February 3, 2021 (Inception) Through March 31, 2021 |
|||||||
| Formation and operating costs |
$ | $ | ||||||
| |
|
|
|
|||||
| Loss from operations |
( |
) |
( |
) | ||||
| Loss on sale of Private Placement Warrants |
( |
) | — | |||||
| Gain on investments held in Trust Account |
— | |||||||
| |
|
|
|
|||||
| Net loss |
$ |
( |
) |
$ |
( |
) | ||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding, Class A ordinary shares |
— | |||||||
| |
|
|
|
|||||
| Basic and diluted net loss per share, Class A ordinary shares |
$ | ( |
) | $ | — | |||
| |
|
|
|
|||||
| Basic and diluted weighted average shares outstanding, Class B ordinary shares |
||||||||
| |
|
|
|
|||||
| Basic and diluted net loss per share, Class B ordinary shares |
$ | ( |
) | $ | ( |
) | ||
| |
|
|
|
|||||
Class A Ordinary Shares |
Class B Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholders’ Deficit |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance at December 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| Proceeds from Initial Public Offering allocated to Public Warrants, net of offering costs |
— | — | — | — | — | |||||||||||||||||||||||
| Issuance of Private Placement Warrants |
— | — | — | — | — | |||||||||||||||||||||||
| Forfeiture of Class B Shares by Sponsor |
— | — | ( |
) | ( |
) | — | — | ||||||||||||||||||||
| Accretion of Class A ordinary shares to redemption amount |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at March 31, 2022 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Class A Ordinary Shares |
Class B Ordinary Shares |
Additional Paid-in Capital |
Accumulated Deficit |
Total Shareholder’s Equity |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance at February 3, 2021 (inception) |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||||||||||
| Issuance of Class B ordinary shares to Sponsor (1) |
— | — | — | |||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at March 31, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(1) |
Includes up to |
Three Months Ended March 31, 2022 |
For the period from February 3, 2021 (inception) through March 31, 2021 |
|||||||
| Cash Flows from Operating Activities: |
||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Payment of formation and operating costs through due to related party |
||||||||
| Payment of formation and operating costs through promissory note - related party |
||||||||
| Loss on sale of Private Placement Warrants |
||||||||
| Realized gain on investments held in Trust Account |
( |
) | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Prepaid expenses |
||||||||
| Accounts payable |
( |
) | ||||||
| Accrued expenses |
||||||||
| Accrued expenses - related party |
||||||||
| |
|
|
|
|||||
| Net cash used in operating activities |
( |
) |
||||||
| |
|
|
|
|||||
| Cash Flows from Investing Activities: |
||||||||
| Cash deposited in Trust Account |
( |
) | ||||||
| |
|
|
|
|||||
| Net cash used in investing activities |
( |
) |
||||||
| |
|
|
|
|||||
| Cash Flows from Financing Activities: |
||||||||
| Proceeds from Initial Public Offering, net of underwriting discount paid |
||||||||
| Proceeds from sale of Private Placement Warrants |
||||||||
| |
|
|
|
|||||
| Net cash provided by financing activities |
||||||||
| |
|
|
|
|||||
| Net Change in Cash |
( |
) |
||||||
| Cash - Beginning of period |
||||||||
| |
|
|
|
|||||
| Cash - End of period |
$ |
$ |
||||||
| |
|
|
|
|||||
| Non-cash investing and financing activities: |
||||||||
| Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred offering costs included in accrued offering costs |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred offering costs included in due to related party |
$ | $ | ||||||
| |
|
|
|
|||||
| Accretion of Class A ordinary shares subject to redemption to redemption value |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred underwriting fee payable |
$ | $ | ||||||
| |
|
|
|
|||||
| Forfeiture of Class B ordinary shares by Sponsor |
$ | $ | ||||||
| |
|
|
|
|||||
March 31, 2022 |
December 31, 2021 |
|||||||
| Gross proceeds |
$ | $ | ||||||
| Less: |
||||||||
| Proceeds allocated to Public Warrants |
( |
) | ( |
) | ||||
| Issuance costs allocated to Class A ordinary shares |
( |
) | ( |
) | ||||
| Plus: |
||||||||
| Accretion of carrying value to redemption value |
||||||||
| |
|
|
|
|||||
| Class A ordinary shares subject to possible redemption |
$ |
$ |
||||||
| |
|
|
|
|||||
Three Months Ended March 31, 2022 |
For the Period From February 3, 2021 (Inception) Through March 31, 2021 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
| Basic and diluted net loss per share: |
||||||||||||||||
| Numerator: |
||||||||||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
| |
|
|
|
|
|
|
|
|||||||||
| Denominator: |
||||||||||||||||
| Basic and diluted weighted average ordinary shares outstanding |
||||||||||||||||
| Basic and diluted net loss per ordinary share |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
| • | at any time after the warrants become exercisable; |
| • | upon a minimum of |
| • | if, and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $ |
| • | if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying such warrants. |
| Description |
Amount at Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
| March 31, 2022 |
||||||||||||||||
| Assets |
||||||||||||||||
| Investments held in Trust Account: |
||||||||||||||||
| U.S. Treasury Securities Money Market Funds |
$ | $ | $ | $ | ||||||||||||
| December 31, 202 1 |
||||||||||||||||
| Assets |
||||||||||||||||
| Investments held in Trust Account: |
||||||||||||||||
| U.S. Treasury Securities Money Market Funds |
$ | $ | $ | $ | ||||||||||||
| * | Filed herewith. |
| ** | Furnished herewith. |
| (1) | Incorporated by reference to the registrant’s Current Report on Form 8-K, filed with the SEC on December 20, 2021. |
SWIFTMERGE ACQUISITION CORP. | ||||||
| Date: May 18, 2022 | By: | /s/ John Bremner | ||||
| Name: | John Bremner | |||||
| Title: | Chief Executive Officer | |||||
SWIFTMERGE ACQUISITION CORP. | ||||||
| Date: May 18, 2022 | By: | /s/ Christopher J. Munyan | ||||
| Name: | Christopher J. Munyan | |||||
| Title: | Chief Financial Officer | |||||